Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript
01:11pm, Thursday, 11'th Mar 2021
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
05:44pm, Monday, 08'th Mar 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
08:48am, Thursday, 25'th Feb 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced t
Why Bausch Health, Oncolytics Biotech, And More Are Moving Today
01:01pm, Wednesday, 17'th Feb 2021
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccine
DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study
08:04am, Tuesday, 15'th Dec 2020
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Co
DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke
08:03am, Thursday, 10'th Dec 2020
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company
DiaMedica Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
09:04am, Thursday, 19'th Nov 2020
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological
DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference
08:30am, Wednesday, 11'th Nov 2020
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders,
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript
12:54am, Sunday, 08'th Nov 2020
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript
DiaMedica Therapeutics to Report Third Quarter 2020 Financial Results and Provide a Business Update November 5, 2020
08:30am, Wednesday, 28'th Oct 2020
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4
DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results
08:05pm, Tuesday, 11'th Aug 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business
DiaMedica Announces Closing of $23 Million Public Offering of Common Shares
08:05pm, Monday, 10'th Aug 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registered public offering of 4,600,000 of its
DiaMedica Therapeutics to Report Second Quarter 2020 Financials and Provide a Business Update August 12, 2020
08:05pm, Thursday, 06'th Aug 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, August 11th. DiaMedica will host a live c
DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares
01:05pm, Thursday, 06'th Aug 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its
DiaMedica Announces Proposed Public Offering of Common Shares
08:01pm, Wednesday, 05'th Aug 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten public offering. In addition,
